We unleash the power of insight, innovation and agility to help transform lives

LEARN MORE ABOUT CHURCHILL PHARMACEUTICALS

Expanding options in oral oncology products

LEARN MORE ABOUT SoluMatrix FINE PARTICLE TECHNOLOGY™

Leveraging SoluMatrix Fine Particle Technology™ to develop therapies for patients living with prostate cancer

LEARN MORE ABOUT OUR PIPELINE
Next
Prev
Arrow Down

Committed to advancing cancer care

Churchill Pharmaceuticals brings true value to cancer care.

Churchill Pharmaceuticals is focused on providing value to cancer care by developing quality orally delivered oncology products with optimized clinical profiles. Our commitment to responsibly deliver these products to the patients, payers and healthcare communities we serve is at the core of our business.

LEARN MORE ABOUT CHURCHILL
value Care

About Us

The Churchill team pairs breadth and depth of experience with an agile, entrepreneurial approach to responsibly develop enhanced oral cancer products

Learn More About Churchill

Pipeline

Leveraging SoluMatrix Fine Particle Technology™ to develop enhanced therapies for patients living with prostate cancer

View Our Pipeline

Technology

Expanding oncology treatment options through the development of SoluMatrix™ oral cancer products

View Our Technology

Latest Media

Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
November 22, 2017

The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers
November 16, 2017

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA™ by the U.S. FDA

KING OF PRUSSIA, Pa., July 20, 2017 /PRNewswire/ -- Churchill Pharmaceuticals, LLC (Churchill), a privately held company devoted to expanding treatment options...
July 20, 2017